Free Trial
→ You're not getting into the SpaceX IPO. Do this instead. (From Behind the Markets) (Ad)tc pixel Free VKTX Stock Alerts

Viking Therapeutics (VKTX) Financials

Viking Therapeutics logo
$30.27 -1.44 (-4.54%)
Closing price 05/15/2026 04:00 PM Eastern
Extended Trading
$30.46 +0.19 (+0.63%)
As of 05/15/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Viking Therapeutics

Annual Income Statements for Viking Therapeutics

This table shows Viking Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -23 -15 -21 -22 -26 -79 -55 -69 -86 -110 -360
Consolidated Net Income / (Loss)		 -23 -15 -21 -22 -26 -39 -55 -69 -86 -110 -360
Net Income / (Loss) Continuing Operations		 -23 -15 -21 -22 -26 -79 -55 -69 -86 -110 -360
Total Pre-Tax Income 		-23 -15 -21 -22 -26 -79 -55 -69 -86 -110 -360
Total Operating Income		 -12 -14 -19 -26 -33 -43 -56 -70 -101 -151 -393
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 12 14 19 26 33 85 56 70 101 151 393
Selling, General & Admin Expense		 5.03 4.85 5.33 7.12 9.13 11 11 16 37 49 48
Research & Development Expense		 6.97 9.00 14 19 24 32 45 54 64 102 345
Amortization Expense		 - - - - - - 0.02 0.06 0.09 0.09 0.06
Total Other Income / (Expense), net		 -11 -0.88 -1.51 4.10 6.91 6.33 0.71 1.55 15 41 34
Interest & Investment Income		 -0.09 -0.02 0.00 3.24 7.05 3.23 0.70 1.59 15 41 34
Other Income / (Expense), net		 -10 0.93 -0.23 1.27 -0.15 3.10 0.01 -0.04 0.00 0.11 0.06
Basic Earnings per Share		 ($3.68) ($0.90) ($0.79) ($0.38) ($0.36) ($0.54) ($0.71) ($0.90) ($0.91) ($1.01) ($3.19)
Weighted Average Basic Shares Outstanding		 6.36M 16.28M 25.98M 57.58M 71.96M 72.60M 77.20M 76.83M 94.35M 109.04M 112.67M
Diluted Earnings per Share		 ($3.68) ($0.90) ($0.79) ($0.38) ($0.36) ($0.54) ($0.71) ($0.90) ($0.91) ($1.01) ($3.19)
Weighted Average Diluted Shares Outstanding		 6.36M 16.28M 25.98M 57.58M 71.96M 72.60M 77.20M 76.83M 94.35M 109.04M 112.67M
Weighted Average Basic & Diluted Shares Outstanding		 6.36M 16.28M 25.98M 57.58M 71.96M 72.60M 77.20M 78.42M 100.49M 112.25M 115.55M

Quarterly Income Statements for Viking Therapeutics

This table shows Viking Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -23 -25 -27 -22 -25 -35 -46 -66 -91 -158 -158
Consolidated Net Income / (Loss)		 -23 -25 -27 -22 -25 -35 -46 -66 -91 -158 -158
Net Income / (Loss) Continuing Operations		 -23 -25 -27 -22 -25 -35 -46 -66 -91 -158 -158
Total Pre-Tax Income 		-23 -25 -27 -22 -25 -35 -46 -66 -91 -158 -158
Total Operating Income		 -27 -29 -34 -34 -37 -46 -55 -75 -99 -165 -164
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Operating Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 27 29 34 34 37 46 55 75 99 165 164
Selling, General & Admin Expense		 8.89 8.78 9.97 10 14 15 14 14 8.61 11 14
Research & Development Expense		 18 21 24 24 23 31 41 60 90 153 150
Amortization Expense		 0.00 - 0.03 0.02 - - 0.02 0.02 - - 0.00
Total Other Income / (Expense), net		 4.73 4.74 6.75 12 12 11 9.86 9.03 7.77 7.09 5.80
Interest & Investment Income		 4.73 4.71 6.75 12 12 11 9.86 9.03 7.77 7.04 5.80
Other Income / (Expense), net		 0.00 0.03 0.00 - 0.09 0.02 0.00 - 0.00 - 0.00
Basic Earnings per Share		 ($0.23) ($0.24) ($0.26) ($0.20) ($0.22) ($0.33) ($0.41) ($0.58) ($0.81) ($1.39) ($1.37)
Weighted Average Basic Shares Outstanding		 99.85M 94.35M 103.46M 110.39M 110.91M 109.04M 112.07M 112.13M 112.32M 112.67M 115.57M
Diluted Earnings per Share		 ($0.23) ($0.24) ($0.26) ($0.20) ($0.22) ($0.33) ($0.41) ($0.58) ($0.81) ($1.39) ($1.37)
Weighted Average Diluted Shares Outstanding		 99.85M 94.35M 103.46M 110.39M 110.91M 109.04M 112.07M 112.13M 112.32M 112.67M 115.57M
Weighted Average Basic & Diluted Shares Outstanding		 100.03M 100.49M 110.27M 110.80M 111.44M 112.25M 112.31M 112.44M 113.04M 115.55M 116.11M

Annual Cash Flow Statements for Viking Therapeutics

This table details how cash moves in and out of Viking Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 0.01 2.31 5.91 7.40 -16 21 -2.75 11 19 -29 139
Net Cash From Operating Activities		 -8.73 -11 -15 -19 -25 -22 -48 -48 -73 -88 -279
Net Cash From Continuing Operating Activities		 -8.73 -11 -15 -19 -25 -22 -48 -48 -73 -88 -279
Net Income / (Loss) Continuing Operations		 -23 -15 -21 -22 -26 -39 -55 -69 -86 -110 -360
Consolidated Net Income / (Loss)		 -23 -15 -21 -22 -26 -39 -55 -69 -86 -110 -360
Amortization Expense		 1.03 2.08 2.94 1.26 1.02 4.19 4.22 1.57 -7.82 -17 -8.80
Non-Cash Adjustments To Reconcile Net Income		 13 0.73 1.11 1.21 5.49 8.40 7.29 9.37 17 31 46
Changes in Operating Assets and Liabilities, net		 0.62 0.85 1.77 0.82 -5.49 5.13 -4.10 9.58 3.23 8.16 44
Net Cash From Investing Activities		 -13 3.03 -1.73 -266 7.46 42 38 55 -179 -553 341
Net Cash From Continuing Investing Activities		 -13 3.03 -1.73 -266 7.46 42 38 55 -179 -553 341
Purchase of Investments		 -16 -17 -23 -348 -362 -281 -168 -121 -478 -1,113 -418
Sale and/or Maturity of Investments		 2.56 20 21 82 370 322 206 176 299 560 759
Net Cash From Financing Activities		 22 10 22 300 0.89 0.95 6.88 4.16 271 612 76
Net Cash From Continuing Financing Activities		 22 10 22 292 0.89 0.95 6.88 4.16 271 612 76
Repurchase of Common Equity		 -2.78 -1.10 -0.50 - -0.07 -0.03 0.00 -6.80 0.00 0.00 0.00
Issuance of Common Equity		 25 12 23 297 1.11 1.27 7.63 0.85 6.77 11 2.49
Other Financing Activities, net		 -0.42 -0.03 -0.02 0.13 -0.15 -0.30 -0.75 10 265 602 74

Quarterly Cash Flow Statements for Viking Therapeutics

This table details how cash moves in and out of Viking Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -32 18 140 -152 6.46 -24 11 -4.05 67 65 -48
Net Cash From Operating Activities		 -20 -18 -6.13 -29 -22 -31 -52 -47 -94 -85 -114
Net Cash From Continuing Operating Activities		 -20 -18 -6.13 -29 -22 -31 -52 -47 -94 -85 -114
Net Income / (Loss) Continuing Operations		 -23 -25 -27 -22 -25 -35 -46 -66 -91 -158 -158
Consolidated Net Income / (Loss)		 -23 -25 -27 -22 -25 -35 -46 -66 -91 -158 -158
Amortization Expense		 -3.07 -2.60 -2.72 -5.34 -4.87 -3.90 -3.00 -2.26 -1.91 -1.64 -1.21
Non-Cash Adjustments To Reconcile Net Income		 4.74 3.99 8.65 6.93 10 5.03 14 14 9.53 8.94 11
Changes in Operating Assets and Liabilities, net		 1.21 5.58 15 -7.86 -2.38 3.10 -18 7.22 -11 65 34
Net Cash From Investing Activities		 -13 36 -460 -126 26 6.58 63 43 160 76 54
Net Cash From Continuing Investing Activities		 -13 36 -460 -126 26 6.58 63 43 160 76 54
Purchase of Investments		 -79 -98 -597 -230 -150 -137 -233 -123 -21 -40 -72
Sale and/or Maturity of Investments		 67 133 137 104 176 144 296 166 181 116 127
Net Cash From Financing Activities		 -0.07 0.19 606 2.91 2.52 1.00 0.35 0.51 0.48 75 12
Net Cash From Continuing Financing Activities		 -0.07 0.19 606 2.91 2.52 1.00 0.35 0.51 0.48 75 12
Issuance of Common Equity		 -0.00 0.19 4.36 - 2.52 1.00 0.35 0.51 0.48 1.16 0.45
Other Financing Activities, net		 -0.07 - 602 -4.39 - - 0.00 - - 74 12

Annual Balance Sheets for Viking Therapeutics

This table presents Viking Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 15 15 22 302 284 257 211 169 368 908 716
Total Current Assets		 15 14 22 302 284 256 211 167 367 907 716
Cash & Equivalents		 0.77 3.08 8.99 25 8.38 29 26 37 56 27 166
Short-Term Investments		 13 10 12 277 267 219 176 119 307 876 540
Prepaid Expenses		 1.10 0.82 1.28 0.61 7.86 7.72 8.43 12 5.15 4.60 9.86
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 0.24 0.56 0.27 0.18 0.76 0.40 0.13 1.49 1.16 1.05 0.13
Other Noncurrent Operating Assets		 0.24 0.56 0.27 0.18 0.76 0.40 0.13 1.49 1.16 1.05 0.13
Total Liabilities & Shareholders' Equity		 15 15 22 302 284 257 211 169 368 908 716
Total Liabilities		 6.71 6.49 8.66 4.56 7.14 12 8.78 23 20 28 77
Total Current Liabilities		 1.98 6.48 8.66 4.55 6.78 12 8.78 22 19 27 77
Accounts Payable		 0.59 1.20 1.53 0.96 2.43 3.99 1.44 8.53 7.51 9.81 53
Accrued Expenses		 1.38 1.24 2.26 3.59 4.04 7.81 7.31 13 11 17 23
Other Current Liabilities		 0.00 0.73 1.40 - 0.30 0.33 0.03 0.30 0.32 0.49 0.14
Total Noncurrent Liabilities		 4.74 0.02 0.00 0.01 0.36 0.06 0.00 1.26 0.94 0.63 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 8.72 8.04 13 298 277 244 202 145 348 880 639
Total Preferred & Common Equity		 8.72 8.04 13 298 277 244 202 145 348 880 639
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 8.72 8.04 13 298 277 244 202 145 349 880 639
Common Stock		 54 68 94 401 406 413 426 445 734 1,369 1,486
Retained Earnings		 -46 -60 -81 -103 -129 -168 -223 -292 -378 -488 -848
Treasury Stock		 - - - - - - 0.00 -6.80 -6.80 0.00 0.00
Accumulated Other Comprehensive Income / (Loss)		 -0.01 -0.01 -0.02 -0.42 0.01 -0.05 -0.55 -1.10 - -0.79 0.38

Quarterly Balance Sheets for Viking Therapeutics

This table presents Viking Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 167 151 401 383 968 947 938 867 828 739 608
Total Current Assets		 165 149 399 381 966 946 937 866 827 739 608
Cash & Equivalents		 29 18 70 37 196 44 50 38 34 100 118
Short-Term Investments		 126 117 323 339 767 898 880 814 774 614 485
Prepaid Expenses		 10 3.93 6.45 5.06 0.64 0.14 6.21 14 19 24 5.25
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 1.54 1.38 1.32 1.36 1.09 1.01 1.16 0.94 0.83 0.71 0.03
Other Noncurrent Operating Assets		 1.54 1.38 1.32 1.36 1.09 1.01 1.16 0.94 0.83 0.71 0.03
Total Liabilities & Shareholders' Equity		 167 151 401 383 968 947 938 867 828 739 608
Total Liabilities		 15 17 15 14 34 26 26 20 32 26 106
Total Current Liabilities		 14 16 13 13 33 25 26 20 32 26 106
Accounts Payable		 3.14 3.80 5.61 5.71 5.23 11 0.25 7.70 5.49 4.41 67
Accrued Expenses		 11 12 7.55 7.38 27 14 25 11 26 21 39
Other Current Liabilities		 0.30 0.31 0.31 0.32 0.33 0.33 0.48 0.50 0.47 0.44 0.00
Total Noncurrent Liabilities		 1.34 1.18 1.10 1.02 0.85 0.77 0.76 0.50 0.41 0.32 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 151 134 386 368 934 921 911 847 795 713 502
Total Preferred & Common Equity		 151 134 386 368 934 921 911 847 795 713 502
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 151 135 386 368 935 923 910 847 796 713 502
Common Stock		 432 453 725 729 1,341 1,351 1,362 1,381 1,395 1,403 1,509
Retained Earnings		 -272 -312 -331 -353 -405 -428 -452 -534 -599 -690 -1,006
Treasury Stock		 -6.80 -6.80 -6.80 -6.80 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accumulated Other Comprehensive Income / (Loss)		 -1.76 - -1.04 -0.91 - - - - - - -0.86

Annual Metrics And Ratios for Viking Therapeutics

This table displays calculated financial ratios and metrics derived from Viking Therapeutics' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -3.38% 49.33% -50.84% -44.51% -34.61% -11.19% -45.48% -33.77% -57.85% -54.29% -139.86%
EBIT Growth		 -5.49% 42.37% -49.33% -29.02% -31.89% -20.49% -40.73% -26.44% -43.23% -49.57% -160.78%
NOPAT Growth		 48.88% -15.43% -37.72% -37.18% -24.95% -30.52% -30.52% -26.35% -43.31% -49.68% -160.63%
Net Income Growth		 -6.94% 37.05% -39.68% -7.22% -16.84% -53.21% -39.23% -25.24% -24.73% -28.02% -227.05%
EPS Growth		 29.64% 75.54% 12.22% 51.90% 5.26% -50.00% -31.48% -26.76% -1.11% -10.99% -215.84%
Operating Cash Flow Growth		 -448.66% -26.80% -33.30% -27.08% -31.98% 12.02% -118.51% -1.70% -51.61% -19.64% -217.45%
Free Cash Flow Firm Growth		 0.00% 61.23% -3.57% -57.90% -54.74% 13.48% -75.84% 8.17% -70.40% -39.67% -138.15%
Invested Capital Growth		 86.27% 44.13% -101.75% -3.63% 139.28% -372.92% 94.58% -4,540.64% -35.45% -87.90% -197.80%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -35.32% 14.80% -3.31% -18.43% -4.95% 23.55% -38.64% -14.28% -11.79% -12.22% -40.64%
EBIT Q/Q Growth		 -33.25% 11.18% -3.31% -15.02% -5.93% 20.38% -33.12% -12.43% -9.60% -12.68% -43.10%
NOPAT Q/Q Growth		 -55.20% 5.99% -3.75% -11.09% -5.95% 14.87% -24.86% -12.42% -9.80% -12.65% -43.12%
Net Income Q/Q Growth		 -38.29% 8.94% -2.19% -5.52% -9.38% -9.72% -2.63% -11.68% -6.24% -10.90% -51.49%
EPS Q/Q Growth		 -36.80% 40.00% -6.76% 19.15% -20.00% -10.20% 0.00% -12.50% 1.09% -9.78% -49.77%
Operating Cash Flow Q/Q Growth		 -48.67% 7.01% -11.16% 6.33% -57.78% 22.32% -16.86% 2.86% -10.07% -18.24% -24.09%
Free Cash Flow Firm Q/Q Growth		 0.00% -1.83% -15.21% 3.29% -47.10% 36.20% -44.05% 8.77% -11.60% -13.10% -10.07%
Invested Capital Q/Q Growth		 -49.72% -16.37% 17.74% -78.76% 132.34% -167.51% 92.73% -171.88% -72.05% -35.62% -4,229.68%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 50.00% 100.03% 100.09% 100.10% 100.09% 100.02%
Interest Burden Percent		 104.38% 114.01% 106.64% 88.62% 78.52% 199.67% 98.74% 97.74% 85.10% 72.85% 91.43%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 349.22% -175.71% -191.36% -14.18% -8.97% -15.15% -24.65% -39.67% -34.79% -17.90% -47.34%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% -1,899.52% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 349.22% -175.71% -191.36% -14.18% -8.97% -15.15% -24.65% -39.67% -34.82% -17.92% -47.34%
Return on Equity Simple (ROE_SIMPLE)		 -268.24% -183.17% -152.84% -7.41% -9.30% -16.16% -27.24% -47.39% -24.65% -12.49% 0.00%
Net Operating Profit after Tax (NOPAT)		 -8.40 -9.69 -13 -18 -23 -30 -39 -49 -71 -106 -275
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -225.13% -46.23% -53.65% -2.35% -1.00% -3.68% -7.11% -10.97% -5.92% -0.68% -10.48%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - -33.89% -20.26% -12.00% -43.08%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -22 -13 -19 -25 -33 -40 -56 -70 -101 -151 -393
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -21 -11 -16 -24 -32 -35 -51 -69 -109 -168 -402
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 3.78 2.98 8.59 1.84 2.09 1.68 1.78 4.96 5.34 5.09 6.22
Price to Tangible Book Value (P/TBV)		 3.78 2.98 8.59 1.84 2.09 1.68 1.78 4.96 5.34 5.09 6.22
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 205.21 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.25 0.41 0.26 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.25 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 0.99 -1.30 -1.25 -1.02 -1.00 -1.00 -1.01 -1.03 -1.05 -1.03 -1.06
Leverage Ratio		 -1.38 1.79 1.70 1.04 1.02 1.04 1.05 1.09 1.09 1.04 1.07
Compound Leverage Factor		 -1.44 2.04 1.82 0.92 0.80 2.07 1.03 1.07 0.93 0.76 0.98
Debt to Total Capital		 19.78% 28.90% 20.40% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 28.90% 20.40% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 19.78% 0.00% 0.00% 0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 80.22% 71.10% 79.60% 100.00% 100.00% 99.99% 100.00% 100.00% 100.11% 100.09% 100.00%
Debt to EBITDA		 -0.10 -0.30 -0.21 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.56 0.91 1.05 0.00 0.00 7.02 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 -0.10 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 -0.26 -0.34 -0.26 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 1.42 1.02 1.28 0.00 0.00 8.32 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 -0.26 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -4.95 -5.90 0.74 72.33 48.88 19.98 23.39 15.87 54.44 95.81 28.72
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -0.08% -0.10% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 7.69 2.16 2.52 66.40 41.83 21.12 23.98 7.61 19.19 33.09 9.33
Quick Ratio		 7.13 2.03 2.38 66.27 40.67 20.48 23.02 7.08 18.92 32.93 9.21
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -29 -11 -12 -18 -28 -24 -43 -39 -67 -94 -231
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 -32.10 -6.22 -8.97 -45.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 -9.77 -6.19 -11.50 -46.42 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -9.77 -6.19 -11.50 -46.42 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -3.23 -1.80 -3.64 -3.77 1.48 -4.04 -0.22 -10 -14 -26 -67
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 20 1.42 -1.83 -0.13 5.25 -5.52 3.82 -9.94 -3.60 -12 -44
Enterprise Value (EV)		 21 14 99 245 304 162 158 565 1,499 3,582 3,271
Market Capitalization		 33 24 116 547 580 411 360 721 1,862 4,484 3,977
Book Value per Share		 $0.90 $0.40 $0.47 $4.17 $3.83 $3.35 $2.58 $1.90 $3.49 $7.91 $5.65
Tangible Book Value per Share		 $0.90 $0.40 $0.47 $4.17 $3.83 $3.35 $2.58 $1.90 $3.49 $7.91 $5.65
Total Capital		 11 11 17 298 277 244 202 145 348 880 639
Total Debt		 2.15 3.27 3.45 0.00 0.00 0.03 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 2.15 0.00 0.00 0.00 0.00 0.03 0.00 0.00 0.00 0.00 0.00
Net Debt		 -12 -9.88 -17 -302 -276 -248 -202 -155 -362 -903 -706
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.88 -2.38 -3.93 -3.94 1.09 -4.41 -0.35 -10 -14 -23 -67
Debt-free Net Working Capital (DFNWC)		 13 11 17 298 277 244 202 145 348 880 639
Net Working Capital (NWC)		 13 7.50 13 298 277 244 202 145 348 880 639
Net Nonoperating Expense (NNE)		 15 5.04 7.23 3.75 2.90 9.63 16 20 15 4.32 84
Net Nonoperating Obligations (NNO)		 -12 -9.85 -17 -302 -276 -248 -202 -155 -362 -906 -706
Total Depreciation and Amortization (D&A)		 1.03 2.08 2.94 1.26 1.02 4.19 4.22 1.57 -7.82 -17 -8.80
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($3.68) ($0.90) ($0.79) ($0.38) ($0.36) ($0.54) ($0.71) ($0.90) ($0.91) ($1.01) ($3.19)
Adjusted Weighted Average Basic Shares Outstanding		 9.68M 23.83M 50.90M 71.99M 72.56M 74.13M 78.36M 76.83M 94.35M 109.04M 112.67M
Adjusted Diluted Earnings per Share		 ($3.68) ($0.90) ($0.79) ($0.38) ($0.36) ($0.54) ($0.71) ($0.90) ($0.91) ($1.01) ($3.19)
Adjusted Weighted Average Diluted Shares Outstanding		 9.68M 23.83M 50.90M 71.99M 72.56M 74.13M 78.36M 76.83M 94.35M 109.04M 112.67M
Adjusted Basic & Diluted Earnings per Share		 ($3.68) ($0.90) ($0.79) ($0.38) ($0.36) ($0.54) ($0.71) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 6.36M 16.28M 25.98M 57.58M 71.96M 72.60M 77.20M 78.42M 100.49M 112.25M 115.55M
Normalized Net Operating Profit after Tax (NOPAT)		 -8.40 -9.69 -13 -18 -23 -30 -39 -49 -71 -106 -275
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -25.09 -7.23 -15.04 -61.62 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 -9.40 -5.42 -10.40 -45.33 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 -25.09 -7.23 -15.04 -61.62 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -9.40 -5.42 -10.40 -45.33 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -11.89% -7.44% -2.43% 0.00% -0.28% -0.07% 0.00% -9.87% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Viking Therapeutics

This table displays calculated financial ratios and metrics derived from Viking Therapeutics' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 - - - - - - - - - - 115,554,295.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - - 115,554,295.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - - -1.37
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -90.98% -56.17% -76.66% -53.76% -36.20% -57.33% -58.91% -95.01% -143.03% -231.85% -182.78%
EBIT Growth		 -68.34% -43.22% -65.91% -43.32% -33.68% -58.00% -62.79% -118.99% -170.24% -256.28% -195.89%
NOPAT Growth		 -68.34% -44.38% -65.91% -43.45% -34.08% -57.89% -62.79% -118.99% -169.62% -256.28% -195.89%
Net Income Growth		 -42.86% -25.80% -40.06% -15.73% -10.68% -43.94% -66.80% -194.66% -264.02% -345.16% -246.98%
EPS Growth		 -9.52% 4.00% -4.00% -5.26% 4.35% -37.50% -57.69% -190.00% -268.18% -321.21% -234.15%
Operating Cash Flow Growth		 -45.63% -61.45% 75.11% -149.35% -11.72% -76.76% -753.13% -65.05% -328.03% -173.53% -117.80%
Free Cash Flow Firm Growth		 -39.66% -297.18% 36.53% 56.06% 2.05% -19.95% -1,790.52% -989.75% -495.97% -199.17% 71.39%
Invested Capital Growth		 -114.04% -35.45% -176.77% -263.13% -138.37% -87.90% 84.41% 50.34% 91.93% -197.80% -1,932.32%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -18.34% -5.01% -15.50% -7.12% -4.83% -21.30% -16.66% -31.41% -30.77% -65.60% 0.63%
EBIT Q/Q Growth		 -14.69% -7.29% -16.48% 0.01% -6.98% -26.81% -20.01% -34.44% -32.16% -67.15% 0.37%
NOPAT Q/Q Growth		 -14.85% -7.41% -16.35% 0.06% -7.35% -26.49% -19.96% -34.44% -32.17% -67.14% 0.37%
Net Income Q/Q Growth		 -17.21% -9.19% -11.18% 18.67% -12.09% -42.01% -28.83% -43.68% -38.48% -73.66% -0.42%
EPS Q/Q Growth		 -21.05% -4.35% -8.33% 23.08% -10.00% -50.00% -24.24% -41.46% -39.66% -71.60% 1.44%
Operating Cash Flow Q/Q Growth		 -71.91% 10.27% 65.23% -364.84% 22.98% -41.98% -67.83% 10.07% -99.75% 9.27% -33.63%
Free Cash Flow Firm Q/Q Growth		 -9.80% -13.99% 75.63% -70.55% -144.75% -39.59% -224.45% 1.69% -33.85% 17.91% 73.51%
Invested Capital Q/Q Growth		 -17.58% -72.05% -94.62% 22.53% 22.82% -35.62% 80.78% -146.80% 87.45% -4,229.68% -51.55%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.01% 100.24% 100.10% 100.00% 100.10% 100.12% 100.05% 100.03% 100.00% 100.01% 100.00%
Interest Burden Percent		 82.64% 83.91% 80.20% 65.31% 68.36% 76.54% 82.22% 87.89% 92.11% 95.70% 96.47%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -31.12% -34.79% -17.55% -14.80% -15.50% -17.90% -14.40% -19.99% -29.23% -47.34% -70.04%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -31.12% -34.82% -17.59% -14.83% -15.48% -17.92% -14.42% -20.02% -29.19% -47.34% -70.05%
Return on Equity Simple (ROE_SIMPLE)		 -21.96% 0.00% -10.04% -10.50% -10.88% 0.00% -15.14% -21.57% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -19 -20 -24 -24 -26 -32 -39 -52 -69 -115 -115
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -1.30% -1.59% -0.63% 0.24% 0.10% -0.48% -0.75% -1.52% -2.65% -5.27% -5.97%
Return On Investment Capital (ROIC_SIMPLE)		 - -5.88% - - - -3.68% -4.58% -6.56% -9.68% -18.04% -22.89%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -27 -29 -34 -34 -36 -46 -55 -75 -99 -165 -164
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -30 -32 -37 -39 -41 -50 -58 -77 -100 -166 -165
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 3.01 5.34 8.77 6.33 7.71 5.09 3.20 3.74 4.15 6.22 7.49
Price to Tangible Book Value (P/TBV)		 3.01 5.34 8.77 6.33 7.71 5.09 3.20 3.74 4.15 6.22 7.49
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.02 -1.05 -1.04 -1.02 -1.02 -1.03 -1.02 -1.02 -1.01 -1.06 -1.08
Leverage Ratio		 1.06 1.09 1.05 1.03 1.03 1.04 1.03 1.03 1.03 1.07 1.09
Compound Leverage Factor		 0.87 0.91 0.84 0.67 0.71 0.80 0.85 0.91 0.95 1.02 1.06
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.11% 100.17% 100.25% 99.82% 100.09% 100.03% 100.02% 99.95% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 45.69 55.08 146.81 136.04 159.54 96.19 81.12 54.97 66.61 29.78 19.00
Noncontrolling Interest Sharing Ratio		 0.00% -0.08% -0.21% -0.17% 0.13% -0.10% -0.10% -0.14% 0.12% 0.00% -0.02%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 28.44 19.19 29.48 37.69 36.47 33.09 44.25 25.86 28.34 9.33 5.72
Quick Ratio		 28.07 18.92 29.38 37.55 36.23 32.93 43.52 25.26 27.41 9.21 5.67
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -15 -17 -3.48 -5.93 -15 -20 -66 -65 -87 -71 -19
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -8.00 -14 -32 -25 -19 -26 -4.97 -12 -1.54 -67 -101
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -4.26 -3.60 -20 -18 -11 -12 27 12 18 -44 -96
Enterprise Value (EV)		 731 1,499 7,239 4,903 6,084 3,582 1,859 2,168 2,240 3,271 3,157
Market Capitalization		 1,107 1,862 8,202 5,845 7,015 4,484 2,711 2,976 2,955 3,977 3,760
Book Value per Share		 $3.68 $3.49 $9.04 $8.37 $8.21 $7.91 $7.55 $7.08 $6.34 $5.65 $4.34
Tangible Book Value per Share		 $3.68 $3.49 $9.04 $8.37 $8.21 $7.91 $7.55 $7.08 $6.34 $5.65 $4.34
Total Capital		 368 348 934 921 911 880 847 795 713 639 502
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -376 -362 -963 -942 -930 -903 -852 -808 -715 -706 -603
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -8.35 -14 -29 -22 -19 -23 -5.41 -13 -1.93 -67 -101
Debt-free Net Working Capital (DFNWC)		 368 348 934 921 911 880 846 795 713 639 502
Net Working Capital (NWC)		 368 348 934 921 911 880 846 795 713 639 502
Net Nonoperating Expense (NNE)		 3.45 4.11 3.50 -1.59 -0.65 3.05 6.80 13 22 42 43
Net Nonoperating Obligations (NNO)		 -376 -362 -966 -946 -931 -906 -852 -808 -715 -706 -603
Total Depreciation and Amortization (D&A)		 -3.07 -2.60 -2.72 -5.34 -4.87 -3.90 -3.00 -2.26 -1.91 -1.64 -1.21
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.23) ($0.24) ($0.26) ($0.20) ($0.22) ($0.33) ($0.41) ($0.58) ($0.81) ($1.39) ($1.37)
Adjusted Weighted Average Basic Shares Outstanding		 99.85M 94.35M 103.46M 110.39M 110.91M 109.04M 112.07M 112.13M 112.32M 112.67M 115.57M
Adjusted Diluted Earnings per Share		 ($0.23) ($0.24) ($0.26) ($0.20) ($0.22) ($0.33) ($0.41) ($0.58) ($0.81) ($1.39) ($1.37)
Adjusted Weighted Average Diluted Shares Outstanding		 99.85M 94.35M 103.46M 110.39M 110.91M 109.04M 112.07M 112.13M 112.32M 112.67M 115.57M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 100.03M 100.49M 110.27M 110.80M 111.44M 112.25M 112.31M 112.44M 113.04M 115.55M 116.11M
Normalized Net Operating Profit after Tax (NOPAT)		 -19 -20 -24 -24 -26 -32 -39 -52 -69 -115 -115
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Here are the most important takeaways from Viking Therapeutics, Inc. (VKTX) based on the quarterly income statements, balance sheets, and cash flow statements from the last four years. The focus is on trends that could matter to retail investors.

  • Liquidity cushion: Viking held a sizable amount of liquidity in mid-2025, with cash and short‑term investments totaling roughly $714 million on the balance sheet (about $100 million in cash and around $614 million in short‑term investments in Q3 2025). This provides a meaningful runway to fund ongoing R&D without immediate debt financing.
  • Ongoing financing support: In Q4 2025, net cash from financing activities was about $75.1 million, and the company has shown multiple quarters of equity financing activity. This indicates continued access to capital to fund operations and the pipeline.
  • Investment activity inflows: Viking has seen substantial cash inflows from investing activities in recent quarters (e.g., net inflows from the sale/maturity of investments, with sizable positive totals in Q3 and Q4 2025). These inflows bolster liquidity beyond operating cash flow.
  • Low leverage with a strong equity base: Across the 2025 period, total liabilities remained modest (approx. $26–33 million per quarter) while total shareholders’ equity was robust (around $712–713 million in mid‑2025), suggesting limited leverage and a substantial equity cushion for ongoing development costs.
  • No product revenue yet: Operating revenue and total revenue were essentially zero in 2025 (and have been minimal or zero in recent years), reflecting that Viking’s pipeline has not yet translated into product sales.
  • R&D and SG&A drive costs: R&D expenses remained very high (Q4 2025: about $153.5 million; Q3 2025: about $90.0 million) along with SG&A in the low to mid‑teens millions, underscoring a heavy burn typical of biotech companies pursuing clinical programs.
  • Dilution and share count: Weighted average shares outstanding in 2025 hovered around 112–116 million, with ongoing equity issuances contributing to dilution risk for existing shareholders.
  • Widening net losses in 2025: Net income deteriorated through 2025, with Q4 2025 net loss around $157.7 million (vs. prior quarters), highlighting a sustained negative bottom line driven by high R&D spend and operating costs.
  • Operating cash burn persists: Net cash from continuing operating activities was about −$85.3 million in Q4 2025 and around −$94.0 million in Q3 2025, indicating ongoing cash burn despite the liquidity buffers.
  • Growing accumulated deficit: Retained earnings declined markedly through 2025 (Q1 2025: −$533.5 million; Q2 2025: −$599.1 million; Q3 2025: −$689.9 million), signaling a rising cumulative loss that will continue to require external funding to sustain operations.
05/16/26 06:53 AM ETAI Generated. May Contain Errors.

Viking Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Viking Therapeutics' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Viking Therapeutics' net income appears to be on an upward trend, with a most recent value of -$359.64 million in 2025, rising from -$23.40 million in 2015. The previous period was -$109.96 million in 2024. View Viking Therapeutics' forecast to see where analysts expect Viking Therapeutics to go next.

Viking Therapeutics' total operating income in 2025 was -$393.34 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $393.40 million

Over the last 10 years, Viking Therapeutics' total revenue changed from $0.00 in 2015 to $0.00 in 2025, a change of 0.0%.

Viking Therapeutics' total liabilities were at $76.67 million at the end of 2025, a 173.4% increase from 2024, and a 1,041.9% increase since 2015.

In the past 10 years, Viking Therapeutics' cash and equivalents has ranged from $768.55 thousand in 2015 to $165.81 million in 2025, and is currently $165.81 million as of their latest financial filing in 2025.

Over the last 10 years, Viking Therapeutics' book value per share changed from 0.90 in 2015 to 5.65 in 2025, a change of 527.1%.


Related Companies

Financial statements for NASDAQ:VKTX last updated on 5/3/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Elon's new "super startup"
Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...
Banyan Hill Publishing | Sponsoredtc pixel
SpaceX is chump change compared to Elon’s $20T ‘iPhone’
Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...
StocksToTrade | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
One coin wired into Elon's vision
The SpaceX IPO is projected to raise $75 billion in a single day... When that happens, the insiders who cashed...
Crypto 101 Media | Sponsoredtc pixel
The cat is out the bag
Almost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered s...
Porter & Company | Sponsoredtc pixel